Global Liver Cancer Treatment Market - 2025-2033
Overview
The global liver cancer treatment market size reached US$ 4.58 billion in 2024 and is expected to reach US$ 12.88 billion by 2033, growing at a CAGR of 11.4% during the forecast period 2025-2033
Liver cancer originates in the cells of the liver, an organ located in the upper right part of the abdomen, just below the diaphragm and above the stomach. Several types of cancer can develop in the liver. The most common is hepatocellular carcinoma, which arises from hepatocytes, the main type of liver cell. Less common forms include intrahepatic cholangiocarcinoma and hepatoblastoma.
There are two main types of liver cancer based on where it starts primary liver cancer, which originates directly in the liver tissue, and secondary (or metastatic) liver cancer, which begins in another part of the body, such as the colon, breast, or lungs, and then spreads to the liver.
The liver plays a critical role in the body's overall function. It filters toxins from the blood, stores essential nutrients, and produces bile, a fluid that helps digest fats. Because of its central role in metabolism and detoxification, any disruption caused by cancer can significantly affect overall health.
HCC often develops in the setting of chronic liver disease, especially conditions like hepatitis B or C infections, alcohol-related liver damage, or non-alcoholic fatty liver disease (NAFLD). Early stages of liver cancer may not show noticeable symptoms, which often leads to late diagnosis when the disease is more advanced and harder to treat. Therefore, early detection and regular screening in at-risk individuals are crucial for improving outcomes.
Market Dynamics: Drivers & Restraints
Advancements in Targeted & Immunotherapies
Recent breakthroughs in targeted therapies and immunotherapies are revolutionizing the way liver cancer is treated. These cutting-edge innovations are enhancing patient outcomes and offering new hope for those affected by the disease.
The rising advancements in targeted therapies have been a significant driver for the growth of the liver cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth.
For instance, in October 2022, the U.S. Food and Drug Administration (FDA) approved a new treatment option for patients with unresectable hepatocellular carcinoma, the most common form of liver cancer. The approved therapy is a combination of two immunotherapy drugs: durvalumab (Imfinzi) and the experimental agent tremelimumab. This marks an important advancement for individuals with liver cancer that cannot be treated with surgery. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for liver cancer patients and expanding the market further.
Side effects and safety concerns associated with the treatment are hampering the market growth
Despite the significant advancements in liver cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. Although recent advancements in targeted therapies and immunotherapies have improved treatment efficacy, many of these options come with serious and sometimes life-threatening adverse effects. For example, immunotherapies such as checkpoint inhibitors can trigger immune-related complications like colitis, pneumonitis, and hepatitis, which may require additional interventions or lead to treatment discontinuation.
Similarly, targeted therapies, including tyrosine kinase inhibitors like sorafenib and lenvatinib, are often associated with high toxicity levels, causing side effects such as hypertension, fatigue, and liver enzyme abnormalities. These concerns are especially critical for liver cancer patients, who often have pre-existing liver dysfunction due to cirrhosis or hepatitis, making them more vulnerable to treatment-related complications. As a result, physicians may hesitate to prescribe aggressive therapies for certain patients, reducing overall adoption rates and slowing market growth.
Epidemiology Analysis
The rising incidence of liver cancer presents significant challenges in the global healthcare landscape. As per DataM intelligence estimates, particularly as its prevalence is expected to increase from an estimated 0.91 million prevalent cases in 2024 to 1.05 million by 2030. This trend highlights the growing need for effective interventions, particularly in regions where liver cancer rates are more pronounced, such as in developing countries and among high-risk populations.
Early detection, better treatment options, and advancements in healthcare systems in developed countries have improved outcomes, but significant challenges remain in developing nations. Addressing these disparities and fostering innovation in treatment options will be crucial for managing the growing burden of liver cancer globally.
Pipeline Analysis
Top Phase Pipeline Products for Liver Cancer:
Segment Analysis
The global liver cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.
Treatment Type:
The targeted therapy segment is expected to dominate the liver cancer treatment market with the highest market share
Targeted therapy has revolutionized the treatment landscape for hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. These therapies are designed to interfere with specific molecular targets involved in tumor growth and progression, offering a more precise approach compared to conventional treatments.
HCC pathogenesis is often driven by aberrant signaling pathways, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and hepatocyte growth factor receptor (c-MET). Targeted therapies aim to inhibit these pathways, thereby impeding tumor angiogenesis, cell proliferation, and survival. By selectively blocking these molecular targets, targeted therapies can effectively suppress tumor growth with potentially fewer side effects than traditional chemotherapy.
Targeted therapies have significantly advanced the treatment of HCC, offering more personalized and effective options for patients. Ongoing research and clinical trials continue to expand the arsenal of targeted agents, potentially improving outcomes for individuals affected by this challenging disease.
Geographical Analysis
North America is expected to hold a significant position in the global liver cancer treatment market with the highest market share
North America is projected to maintain a dominant position in the global liver cancer treatment market, driven by several key factors includes high incidence and mortality rates as per America Cancer Society data in February 2025, in the United States, in particular, reports a significant number of liver cancer cases annually, with approximately 42,240 men and 14.020 women diagnosed each year.
Despite recent declines, liver cancer remains a major health concern, contributing to substantial morbidity and mortality. This high incidence underscores the urgent need for effective treatment options and drives market demand.
North America's well-established healthcare infrastructure facilitates the rapid adoption of innovative treatments. The region boasts state-of-the-art medical facilities, a robust regulatory framework, and a high level of healthcare access, ensuring that patients receive timely and effective care. These factors contribute to the region's leading position in the liver cancer treatment market.
For instance, in April 2025, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The presence of major pharmaceutical companies and research institutions in North America accelerates the development of novel therapeutics. Ongoing research and clinical trials lead to the introduction of advanced treatment options, including targeted therapies and immunotherapies, enhancing patient outcomes and expanding market opportunities.
Competitive Landscape
Top companies in the liver cancer treatment market include Eli Lilly and Company, AstraZeneca, Eisai Inc., TAIHO ONCOLOGY, INC., Bayer AG, Bristol-Myers Squibb Company., Incyte, Genentech USA, Inc., Exelixis, Inc., and Merck & Co., Inc., among others.
Key Developments
Target Audience 2024
The global liver cancer treatment market size reached US$ 4.58 billion in 2024 and is expected to reach US$ 12.88 billion by 2033, growing at a CAGR of 11.4% during the forecast period 2025-2033
Liver cancer originates in the cells of the liver, an organ located in the upper right part of the abdomen, just below the diaphragm and above the stomach. Several types of cancer can develop in the liver. The most common is hepatocellular carcinoma, which arises from hepatocytes, the main type of liver cell. Less common forms include intrahepatic cholangiocarcinoma and hepatoblastoma.
There are two main types of liver cancer based on where it starts primary liver cancer, which originates directly in the liver tissue, and secondary (or metastatic) liver cancer, which begins in another part of the body, such as the colon, breast, or lungs, and then spreads to the liver.
The liver plays a critical role in the body's overall function. It filters toxins from the blood, stores essential nutrients, and produces bile, a fluid that helps digest fats. Because of its central role in metabolism and detoxification, any disruption caused by cancer can significantly affect overall health.
HCC often develops in the setting of chronic liver disease, especially conditions like hepatitis B or C infections, alcohol-related liver damage, or non-alcoholic fatty liver disease (NAFLD). Early stages of liver cancer may not show noticeable symptoms, which often leads to late diagnosis when the disease is more advanced and harder to treat. Therefore, early detection and regular screening in at-risk individuals are crucial for improving outcomes.
Market Dynamics: Drivers & Restraints
Advancements in Targeted & Immunotherapies
Recent breakthroughs in targeted therapies and immunotherapies are revolutionizing the way liver cancer is treated. These cutting-edge innovations are enhancing patient outcomes and offering new hope for those affected by the disease.
The rising advancements in targeted therapies have been a significant driver for the growth of the liver cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth.
For instance, in October 2022, the U.S. Food and Drug Administration (FDA) approved a new treatment option for patients with unresectable hepatocellular carcinoma, the most common form of liver cancer. The approved therapy is a combination of two immunotherapy drugs: durvalumab (Imfinzi) and the experimental agent tremelimumab. This marks an important advancement for individuals with liver cancer that cannot be treated with surgery. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for liver cancer patients and expanding the market further.
Side effects and safety concerns associated with the treatment are hampering the market growth
Despite the significant advancements in liver cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. Although recent advancements in targeted therapies and immunotherapies have improved treatment efficacy, many of these options come with serious and sometimes life-threatening adverse effects. For example, immunotherapies such as checkpoint inhibitors can trigger immune-related complications like colitis, pneumonitis, and hepatitis, which may require additional interventions or lead to treatment discontinuation.
Similarly, targeted therapies, including tyrosine kinase inhibitors like sorafenib and lenvatinib, are often associated with high toxicity levels, causing side effects such as hypertension, fatigue, and liver enzyme abnormalities. These concerns are especially critical for liver cancer patients, who often have pre-existing liver dysfunction due to cirrhosis or hepatitis, making them more vulnerable to treatment-related complications. As a result, physicians may hesitate to prescribe aggressive therapies for certain patients, reducing overall adoption rates and slowing market growth.
Epidemiology Analysis
The rising incidence of liver cancer presents significant challenges in the global healthcare landscape. As per DataM intelligence estimates, particularly as its prevalence is expected to increase from an estimated 0.91 million prevalent cases in 2024 to 1.05 million by 2030. This trend highlights the growing need for effective interventions, particularly in regions where liver cancer rates are more pronounced, such as in developing countries and among high-risk populations.
Early detection, better treatment options, and advancements in healthcare systems in developed countries have improved outcomes, but significant challenges remain in developing nations. Addressing these disparities and fostering innovation in treatment options will be crucial for managing the growing burden of liver cancer globally.
Pipeline Analysis
Top Phase Pipeline Products for Liver Cancer:
Segment Analysis
The global liver cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.
Treatment Type:
The targeted therapy segment is expected to dominate the liver cancer treatment market with the highest market share
Targeted therapy has revolutionized the treatment landscape for hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. These therapies are designed to interfere with specific molecular targets involved in tumor growth and progression, offering a more precise approach compared to conventional treatments.
HCC pathogenesis is often driven by aberrant signaling pathways, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and hepatocyte growth factor receptor (c-MET). Targeted therapies aim to inhibit these pathways, thereby impeding tumor angiogenesis, cell proliferation, and survival. By selectively blocking these molecular targets, targeted therapies can effectively suppress tumor growth with potentially fewer side effects than traditional chemotherapy.
Targeted therapies have significantly advanced the treatment of HCC, offering more personalized and effective options for patients. Ongoing research and clinical trials continue to expand the arsenal of targeted agents, potentially improving outcomes for individuals affected by this challenging disease.
Geographical Analysis
North America is expected to hold a significant position in the global liver cancer treatment market with the highest market share
North America is projected to maintain a dominant position in the global liver cancer treatment market, driven by several key factors includes high incidence and mortality rates as per America Cancer Society data in February 2025, in the United States, in particular, reports a significant number of liver cancer cases annually, with approximately 42,240 men and 14.020 women diagnosed each year.
Despite recent declines, liver cancer remains a major health concern, contributing to substantial morbidity and mortality. This high incidence underscores the urgent need for effective treatment options and drives market demand.
North America's well-established healthcare infrastructure facilitates the rapid adoption of innovative treatments. The region boasts state-of-the-art medical facilities, a robust regulatory framework, and a high level of healthcare access, ensuring that patients receive timely and effective care. These factors contribute to the region's leading position in the liver cancer treatment market.
For instance, in April 2025, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The presence of major pharmaceutical companies and research institutions in North America accelerates the development of novel therapeutics. Ongoing research and clinical trials lead to the introduction of advanced treatment options, including targeted therapies and immunotherapies, enhancing patient outcomes and expanding market opportunities.
Competitive Landscape
Top companies in the liver cancer treatment market include Eli Lilly and Company, AstraZeneca, Eisai Inc., TAIHO ONCOLOGY, INC., Bayer AG, Bristol-Myers Squibb Company., Incyte, Genentech USA, Inc., Exelixis, Inc., and Merck & Co., Inc., among others.
Key Developments
- In April 2025, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- In February 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BST02, an investigational T-cell therapy developed by Biosyngen, for the treatment of all forms of liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma. This designation aims to expedite the development and review processes for therapies addressing serious conditions with unmet medical needs.
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in Targeted & Immunotherapies
3.1.1.2. Expanding Clinical Trials and Research Investment
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Safety Concerns
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Combination & Multimodal Therapy Strategies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. LIVER CANCER TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Hepatocellular Carcinoma*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Cholangiocarcinoma
5.4. Others
6. LIVER CANCER TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Targeted Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Ramucirumab
6.2.4. Cabozantinib
6.2.5. Lenvatinib Mesylate
6.2.6. Futibatinib
6.2.7. Pemigatinib
6.2.8. Regorafenib
6.2.9. Sorafenib Tosylate
6.2.10. Others
6.3. Immunotherapy
6.3.1. Pembrolizumab
6.3.2. Durvalumab
6.3.3. Tremelimumab-actl
6.3.4. Nivolumab
6.3.5. Atezolizumab
6.3.6. Ipilimumab
6.3.7. Others
6.4. Chemotherapy
6.5. Radiation Therapy
6.6. Surgery
6.7. Ablation and Embolization Therapies
6.8. Others
7. LIVER CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Injectable*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral
8. LIVER CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Eli Lilly and Company
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. Eisai Inc.
10.4. TAIHO ONCOLOGY, INC.
10.5. Bayer AG
10.6. Bristol-Myers Squibb Company.
10.7. Incyte.
10.8. Genentech USA, Inc.
10.9. Exelixis, Inc.
10.10. Merck & Co., Inc.
LIST NOT EXHAUSTIVE
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Advancements in Targeted & Immunotherapies
3.1.1.2. Expanding Clinical Trials and Research Investment
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Safety Concerns
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Combination & Multimodal Therapy Strategies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. LIVER CANCER TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Hepatocellular Carcinoma*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Cholangiocarcinoma
5.4. Others
6. LIVER CANCER TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Targeted Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Ramucirumab
6.2.4. Cabozantinib
6.2.5. Lenvatinib Mesylate
6.2.6. Futibatinib
6.2.7. Pemigatinib
6.2.8. Regorafenib
6.2.9. Sorafenib Tosylate
6.2.10. Others
6.3. Immunotherapy
6.3.1. Pembrolizumab
6.3.2. Durvalumab
6.3.3. Tremelimumab-actl
6.3.4. Nivolumab
6.3.5. Atezolizumab
6.3.6. Ipilimumab
6.3.7. Others
6.4. Chemotherapy
6.5. Radiation Therapy
6.6. Surgery
6.7. Ablation and Embolization Therapies
6.8. Others
7. LIVER CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Injectable*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral
8. LIVER CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Eli Lilly and Company
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. AstraZeneca
10.3. Eisai Inc.
10.4. TAIHO ONCOLOGY, INC.
10.5. Bayer AG
10.6. Bristol-Myers Squibb Company.
10.7. Incyte.
10.8. Genentech USA, Inc.
10.9. Exelixis, Inc.
10.10. Merck & Co., Inc.
LIST NOT EXHAUSTIVE
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Liver Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Liver Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Liver Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Liver Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Liver Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 7 Global Liver Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 9 Global Liver Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 11 Global Liver Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Liver Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 North America Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 North America Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 16 North America Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 South America Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 South America Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 19 South America Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 20 South America Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 22 Europe Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Eli Lilly and Company: Overview
Table 34 Eli Lilly and Company: Product Portfolio
Table 35 Eli Lilly and Company: Key Developments
Table 36 AstraZeneca: Overview
Table 37 AstraZeneca: Product Portfolio
Table 38 AstraZeneca: Key Developments
Table 39 Eisai Inc. : Overview
Table 40 Eisai Inc. : Product Portfolio
Table 41 Eisai Inc. : Key Developments
Table 42 TAIHO ONCOLOGY, INC.: Overview
Table 43 TAIHO ONCOLOGY, INC.: Product Portfolio
Table 44 TAIHO ONCOLOGY, INC.: Key Developments
Table 45 Bayer AG: Overview
Table 46 Bayer AG: Product Portfolio
Table 47 Bayer AG: Key Developments
Table 48 Bristol-Myers Squibb Company.: Overview
Table 49 Bristol-Myers Squibb Company.: Product Portfolio
Table 50 Bristol-Myers Squibb Company.: Key Developments
Table 51 Incyte. : Overview
Table 52 Incyte. : Product Portfolio
Table 53 Incyte. : Key Developments
Table 54 Genentech USA, Inc. : Overview
Table 55 Genentech USA, Inc. : Product Portfolio
Table 56 Genentech USA, Inc. : Key Developments
Table 57 Exelixis, Inc. : Overview
Table 58 Exelixis, Inc. : Product Portfolio
Table 59 Exelixis, Inc. : Key Developments
Table 60 Merck & Co., Inc.: Overview
Table 61 Merck & Co., Inc.: Product Portfolio
Table 62 Merck & Co., Inc.: Key Developments
Table 1 Global Liver Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Liver Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Liver Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Liver Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Liver Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 7 Global Liver Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 9 Global Liver Cancer Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 11 Global Liver Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Liver Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 North America Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 North America Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 16 North America Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 South America Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 South America Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 19 South America Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 20 South America Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 22 Europe Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Europe Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Liver Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Liver Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Liver Cancer Treatment Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Liver Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Eli Lilly and Company: Overview
Table 34 Eli Lilly and Company: Product Portfolio
Table 35 Eli Lilly and Company: Key Developments
Table 36 AstraZeneca: Overview
Table 37 AstraZeneca: Product Portfolio
Table 38 AstraZeneca: Key Developments
Table 39 Eisai Inc. : Overview
Table 40 Eisai Inc. : Product Portfolio
Table 41 Eisai Inc. : Key Developments
Table 42 TAIHO ONCOLOGY, INC.: Overview
Table 43 TAIHO ONCOLOGY, INC.: Product Portfolio
Table 44 TAIHO ONCOLOGY, INC.: Key Developments
Table 45 Bayer AG: Overview
Table 46 Bayer AG: Product Portfolio
Table 47 Bayer AG: Key Developments
Table 48 Bristol-Myers Squibb Company.: Overview
Table 49 Bristol-Myers Squibb Company.: Product Portfolio
Table 50 Bristol-Myers Squibb Company.: Key Developments
Table 51 Incyte. : Overview
Table 52 Incyte. : Product Portfolio
Table 53 Incyte. : Key Developments
Table 54 Genentech USA, Inc. : Overview
Table 55 Genentech USA, Inc. : Product Portfolio
Table 56 Genentech USA, Inc. : Key Developments
Table 57 Exelixis, Inc. : Overview
Table 58 Exelixis, Inc. : Product Portfolio
Table 59 Exelixis, Inc. : Key Developments
Table 60 Merck & Co., Inc.: Overview
Table 61 Merck & Co., Inc.: Product Portfolio
Table 62 Merck & Co., Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Liver Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Liver Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 7 Hepatocellular Carcinoma Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Cholangiocarcinoma Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Others Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Liver Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 11 Targeted therapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Immunotherapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Chemotherapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Radiation Therapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Surgery Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Ablation and Embolization Therapies Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Others Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Liver Cancer Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 19 Injectable Route of Administration in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Oral Route of Administration in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Liver Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 24 North America Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 25 North America Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 26 North America Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 27 South America Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 South America Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 29 South America Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 30 South America Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 31 South America Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 33 Europe Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 34 Europe Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 35 Europe Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 36 Europe Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 37 Asia-Pacific Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 38 Asia-Pacific Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 39 Asia-Pacific Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 41 Asia-Pacific Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 45 Middle East and Africa Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 46 Eli Lilly and Company: Financials
Figure 47 AstraZeneca: Financials
Figure 48 Eisai Inc. : Financials
Figure 49 TAIHO ONCOLOGY, INC.: Financials
Figure 50 Bayer AG: Financials
Figure 51 Bristol-Myers Squibb Company.: Financials
Figure 52 Incyte. : Financials
Figure 53 Genentech USA, Inc. : Financials
Figure 54 Exelixis, Inc. : Financials
Figure 55 Merck & Co., Inc.: Financials
Figure 1 Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Liver Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Liver Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 7 Hepatocellular Carcinoma Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Cholangiocarcinoma Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Others Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Liver Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 11 Targeted therapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Immunotherapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Chemotherapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Radiation Therapy Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Surgery Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Ablation and Embolization Therapies Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Others Treatment Type in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 Global Liver Cancer Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 19 Injectable Route of Administration in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Oral Route of Administration in Global Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Liver Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 24 North America Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 25 North America Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 26 North America Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 27 South America Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 South America Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 29 South America Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 30 South America Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 31 South America Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 33 Europe Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 34 Europe Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 35 Europe Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 36 Europe Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 37 Asia-Pacific Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 38 Asia-Pacific Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 39 Asia-Pacific Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 41 Asia-Pacific Liver Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Liver Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Liver Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Liver Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 45 Middle East and Africa Liver Cancer Treatment Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 46 Eli Lilly and Company: Financials
Figure 47 AstraZeneca: Financials
Figure 48 Eisai Inc. : Financials
Figure 49 TAIHO ONCOLOGY, INC.: Financials
Figure 50 Bayer AG: Financials
Figure 51 Bristol-Myers Squibb Company.: Financials
Figure 52 Incyte. : Financials
Figure 53 Genentech USA, Inc. : Financials
Figure 54 Exelixis, Inc. : Financials
Figure 55 Merck & Co., Inc.: Financials
